Top FDA Data Integrity Violations

Data integrity has become one of the most closely scrutinized areas during FDA inspections. When data isn’t reliable, regulators view it as a direct threat to product quality, patient safety, and trust in the healthcare system. The most common violations aren’t isolated mistakes, but rather ones that reveal deeper issues in quality culture, documentation practices, and system controls. 

Many of these violations represent a clear breach of the ALCOA principles: Attributable, Legible, Contemporaneous, Original, and Accurate. Below are the top FDA data integrity violations cited in warning letters —and what they mean for regulated organizations. 

Top FDA Data Integrity Violations

1. Data Falsification and Manipulation

These violations signal an intent to hide or alter unfavorable results, making them some of the most serious findings: 

• “Testing into Compliance” (Trial Runs): Running preliminary or “trial” analytical injections of a sample to see if it passes specifications, then deleting the initial runs and only reporting the final passing result. 

• Unauthorized Deletion or Alteration: Deleting, discarding, or modifying electronic raw data (such as chromatography files) or paper records without proper review, justification, or audit trail capture. 

• Backdating and Falsifying Records: Fabricating dates, signatures, or test results, or recording data long after the work was actually performed, violating the Contemporaneous principle. 

When this happens, the integrity of the entire data set is compromised, creating serious regulatory and operational risks. 

2. Inadequate Controls Over Computerized Systems

A lack of proper system security and control often enables data manipulation. Common findings include: 

• Shared or Generic User Accounts: Using non-unique logins and passwords for critical systems (e.g., lab equipment) makes it impossible to trace an action to a specific individual, violating the Attributable principle. 

• Insufficient Access Controls: Granting personnel system administration rights to unauthorized individuals that allow them to change configurations, delete files, or modify audit trails. 

• Lack of Audit Trail Review: Failing to establish written procedures or regularly review the electronic audit trails that record all additions, deletions, or modifications to the data. 

When systems lack clear traceability, regulators view it as a major gap in accountability and compliance. 

3. Documentation and Procedural Failures

Even the most advanced systems can’t protect data integrity without strong procedural foundations. These failures are often rooted in weak Quality Management Systems (QMS) and poor governance: 

• Incomplete Data Retention: Failing to capture and retain the complete set of raw data, metadata, and audit trails. For example, retaining only static printouts instead of dynamic electronic data. 

• Failure to Investigate OOS Results: Re-testing samples without scientifically sound justification after an Out-of-Specification (OOS) result, instead of conducting a thorough investigation to find the root cause. 

• Lack of Written Procedures: Not having established, detailed, and clear Standard Operating Procedures (SOPs) for data review, system access, or data backup and archiving. 

These issues create blind spots that increase the risk of noncompliance and regulatory action. 

Preventing Data Integrity Violations 

Building a culture of quality requires more than policies on paper. It involves secure systems, clear procedures, proper training, and ongoing oversight. Organizations can reduce risk by: 

• Enforcing unique user access and password controls 

• Regularly reviewing audit trails and metadata 

• Implementing validated systems with strong security features 

• Maintaining complete and contemporaneous records 

• Training staff on ALCOA principles and data handling expectations 

Modern digital solutions like ACE provide built-in security, audit trail visibility, and document control capabilities designed to support ALCOA compliance and cGMP expectations. With the right systems in place, teams can focus on quality while maintaining full regulatory readiness. 

The Bottom Line: Data Integrity Is Non-Negotiable 

Data integrity is a cornerstone of regulatory compliance. FDA enforcement trends show a continued emphasis on accountability and quality culture. When organizations design systems and environments that protect data and empower employees to do the right thing, they significantly reduce the risk of violations. 

Failure to address these issues can lead to severe regulatory actions, including Warning Letters, Import Alerts, and product recalls. By investing in secure, validated systems and robust processes, organizations can safeguard their reputation, ensure patient safety, and maintain compliance.